Literature DB >> 14503112

Association of hyperglycemia and markers of hepatic dysfunction with dextrose infusion rates in Korean patients receiving total parenteral nutrition.

Hyunah Kim1, Eunsun Son, Jungtae Kim, Kyungeob Choi, Choongbae Kim, Wangyoon Shin, Okkyung Suh.   

Abstract

The association of hyperglycemia and markers of hepatic dysfunction with dextrose infusion rates in Korean patients receiving total parenteral nutrition (TPN) was studied. A retrospective study of 122 patients with normal glucose levels and liver function tests (LFTs) was conducted. Pharmacy and medical records of all patients who received TPN from three university-affiliated teaching hospitals in Korea between January 1998 and December 1999 were reviewed. Each patient was categorized as receiving dextrose at (1) < or = 5 or > 5 mg/kg/min and (2) < or = 4, 4.1-5, 5.1-6, or > 6 mg/kg/min. Fifty-five patients received dextrose at a rate of > 5 mg/kg/min for 15.1 +/- 12.8 days and 67 patients at a rate of < or = 5 mg/kg/min for 10.1 +/- 6.8 days. Two patients in each group did not have follow-up glucose levels. Of the 53 patients in the > 5 mg/kg/min group, 16 exhibited hyperglycemia, compared with 21 of the 65 receiving lower rates of dextrose infusion. Elevated aspartate transaminase was the most common abnormal LFT value in both groups (25% and 29% in the < or = 5- and > 5-mg/kg/min groups, respectively). In the group receiving dextrose at > 5 mg/kg/min, 22.2% had two hepatic enzyme levels elevated concurrently, while 18.5% had two hepatic enzyme levels elevated in the group receiving dextrose at < or = 5 mg/kg/min. Regression analysis revealed that duration of TPN and dextrose infusion rate were positively correlated with blood glucose levels and that duration of TPN was positively correlated with abnormal LFT values. A retrospective study of Korean patients revealed no significant difference in the risk of hyperglycemia or hepatic dysfunction between those receiving < or = 5 and > 5 mg/kg/min dextrose infusion in their TPN.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14503112     DOI: 10.1093/ajhp/60.17.1760

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  5 in total

1.  Overview of glycemic control in critical care: relating performance and clinical results.

Authors:  J Geoffrey Chase; Christopher E Hann; Geoffrey M Shaw; Jason Wong; Jessica Lin; Thomas Lotz; Aaron Lecompte; Timothy Lonergan
Journal:  J Diabetes Sci Technol       Date:  2007-01

2.  A benchmark data set for model-based glycemic control in critical care.

Authors:  J Geoffrey Chase; Aaron LeCompte; Geoffrey M Shaw; Amy Blakemore; Jason Wong; Jessica Lin; Christopher E Hann
Journal:  J Diabetes Sci Technol       Date:  2008-07

3.  Management of glycemic variation in diabetic patients receiving parenteral nutrition by continuous subcutaneous insulin infusion (CSII) therapy.

Authors:  Feng-Fei Li; Wen-Li Zhang; Bing-Li Liu; Dan-Feng Zhang; Wei Chen; Li Yuan; Mao-Yuan Chen; Xiao-Fang Zhai; Jin-Dan Wu; Xiao-Fei Su; Lei Ye; Hong-Yong Cao; Jian-Hua Ma
Journal:  Sci Rep       Date:  2018-04-12       Impact factor: 4.379

Review 4.  Complications and monitoring - Guidelines on Parenteral Nutrition, Chapter 11.

Authors:  W H Hartl; K W Jauch; K Parhofer; P Rittler
Journal:  Ger Med Sci       Date:  2009-11-18

5.  Implementation and evaluation of the SPRINT protocol for tight glycaemic control in critically ill patients: a clinical practice change.

Authors:  J Geoffrey Chase; Geoffrey Shaw; Aaron Le Compte; Timothy Lonergan; Michael Willacy; Xing-Wei Wong; Jessica Lin; Thomas Lotz; Dominic Lee; Christopher Hann
Journal:  Crit Care       Date:  2008-04-16       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.